|
NZ600758A
(en)
|
2007-06-18 |
2013-09-27 |
Merck Sharp & Dohme |
Antibodies to human programmed death receptor pd-1
|
|
US9416132B2
(en)
|
2011-07-21 |
2016-08-16 |
Tolero Pharmaceuticals, Inc. |
Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
HRP20191865T1
(hr)
|
2013-01-14 |
2020-01-10 |
Xencor, Inc. |
Novi heterodimerni proteini
|
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
EP3757130A1
(en)
|
2013-09-26 |
2020-12-30 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
|
PE20160953A1
(es)
|
2013-12-12 |
2016-09-26 |
Shanghai hengrui pharmaceutical co ltd |
Anticuerpo pd-1, fragmento de union al antigeno de este y uso medico de este
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
ME03558B
(me)
|
2014-03-14 |
2020-07-20 |
Novartis Ag |
Molekuli anti-lag-3 antiтela i njihove upotrebe
|
|
EP3954713A3
(en)
|
2014-03-28 |
2022-03-30 |
Xencor, Inc. |
Bispecific antibodies that bind to cd38 and cd3
|
|
SMT202100116T1
(it)
|
2014-05-28 |
2021-05-07 |
Agenus Inc |
Anticorpi anti-gitr e metodi di utilizzo degli stessi
|
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
|
JO3663B1
(ar)
*
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
|
KR20170060042A
(ko)
|
2014-09-13 |
2017-05-31 |
노파르티스 아게 |
Alk 억제제의 조합 요법
|
|
EA201790737A1
(ru)
*
|
2014-10-03 |
2017-08-31 |
Новартис Аг |
Комбинированная терапия
|
|
MX389663B
(es)
|
2014-10-14 |
2025-03-20 |
Novartis Ag |
Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas.
|
|
EP3223907A2
(en)
|
2014-11-26 |
2017-10-04 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cd38
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
CN116333153A
(zh)
|
2014-11-26 |
2023-06-27 |
森科股份有限公司 |
结合cd3和肿瘤抗原的异二聚体抗体
|
|
WO2016105450A2
(en)
|
2014-12-22 |
2016-06-30 |
Xencor, Inc. |
Trispecific antibodies
|
|
CA2976926A1
(en)
|
2015-02-19 |
2016-08-25 |
Compugen Ltd. |
Anti-pvrig antibodies and methods of use
|
|
TWI716405B
(zh)
|
2015-05-07 |
2021-01-21 |
美商艾吉納斯公司 |
抗ox40抗體及其使用方法
|
|
JP6510075B2
(ja)
|
2015-05-18 |
2019-05-08 |
トレロ ファーマシューティカルズ， インコーポレイテッド |
バイオアベイラビリティが高いアルボシジブプロドラッグ
|
|
CN107849144B
(zh)
|
2015-05-29 |
2021-09-17 |
艾吉纳斯公司 |
抗-ctla-4抗体及其使用方法
|
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
|
HK1248115A1
(zh)
*
|
2015-07-16 |
2018-10-12 |
Bioxcel Therapeutics, Inc. |
一种使用免疫调节治疗癌症的新颖方法
|
|
CN116333138A
(zh)
|
2015-07-30 |
2023-06-27 |
宏观基因有限公司 |
Pd-1结合分子和其使用方法
|
|
PE20180773A1
(es)
|
2015-10-02 |
2018-05-07 |
Hoffmann La Roche |
Anticuerpos biespecificos para pd1 y tim3
|
|
TWI756187B
(zh)
|
2015-10-09 |
2022-03-01 |
美商再生元醫藥公司 |
抗ｌａｇ３抗體及其用途
|
|
EP3383430A4
(en)
|
2015-12-02 |
2019-12-18 |
Agenus Inc. |
ANTIBODIES AND METHOD FOR USE THEREOF
|
|
KR20180085800A
(ko)
|
2015-12-07 |
2018-07-27 |
젠코어 인코포레이티드 |
Cd3 및 psma에 결합하는 이종이합체성 항체
|
|
TW202208440A
(zh)
|
2015-12-14 |
2022-03-01 |
美商宏觀基因股份有限公司 |
對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法
|
|
MX2018007406A
(es)
*
|
2015-12-16 |
2018-08-15 |
Merck Sharp & Dohme |
Anticuerpos anti-lag3 y fragmentos de enlace al antigeno.
|
|
AU2017222928A1
(en)
*
|
2016-02-26 |
2018-09-20 |
Eli Lilly And Company |
Anti-CD11d antibodies and uses thereof
|
|
CA3058503A1
(en)
|
2016-04-06 |
2017-10-12 |
Noxopharm Limited |
Isoflavonoid composition with improved pharmacokinetics
|
|
TWI808055B
(zh)
|
2016-05-11 |
2023-07-11 |
美商滬亞生物國際有限公司 |
Hdac 抑制劑與 pd-1 抑制劑之組合治療
|
|
TWI794171B
(zh)
|
2016-05-11 |
2023-03-01 |
美商滬亞生物國際有限公司 |
Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
|
|
MA55697A
(fr)
*
|
2016-05-18 |
2022-02-23 |
Boehringer Ingelheim Int |
Molécules d'anticorps pour le traitement du cancer
|
|
CN109689694B
(zh)
|
2016-05-19 |
2022-11-22 |
通用医疗公司 |
与其受体IL-2Rβ结合的IL2作为用来增强自然杀伤细胞和调节性T细胞活性的平台
|
|
MA45123A
(fr)
|
2016-05-27 |
2019-04-10 |
Agenus Inc |
Anticorps anti-tim-3 et leurs méthodes d'utilisation
|
|
CA3029813A1
(en)
|
2016-06-13 |
2017-12-21 |
Torque Therapeutics, Inc. |
Methods and compositions for promoting immune cell function
|
|
IL263542B2
(en)
|
2016-06-14 |
2024-10-01 |
Xencor Inc |
Bispecific antibodies inhibit immunological checkpoint
|
|
US11214618B2
(en)
|
2016-06-20 |
2022-01-04 |
F-Star Therapeutics Limited |
LAG-3 binding members
|
|
BR112018076260A2
(pt)
|
2016-06-20 |
2019-03-26 |
Kymab Limited |
anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
|
|
US11214620B2
(en)
|
2016-06-20 |
2022-01-04 |
F-Star Therapeutics Limited |
Binding molecules binding PD-L1 and LAG-3
|
|
HUE058657T2
(hu)
*
|
2016-06-23 |
2022-09-28 |
Jiangsu Hengrui Medicine Co |
Lag-3 antitest, antigénkötõ fragmentuma és gyógyszerészeti alkalmazása
|
|
KR20190020341A
(ko)
|
2016-06-28 |
2019-02-28 |
젠코어 인코포레이티드 |
소마토스타틴 수용체 2에 결합하는 이종이량체 항체
|
|
GB201612520D0
(en)
|
2016-07-19 |
2016-08-31 |
F-Star Beta Ltd |
Binding molecules
|
|
NL2017270B1
(en)
*
|
2016-08-02 |
2018-02-09 |
Aduro Biotech Holdings Europe B V |
New anti-hCTLA-4 antibodies
|
|
CN109790532B
(zh)
*
|
2016-08-15 |
2022-06-17 |
国立大学法人北海道大学 |
抗lag-3抗体
|
|
IL301682B2
(en)
|
2016-08-17 |
2025-06-01 |
Compugen Ltd |
Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
SG10201912764TA
(en)
*
|
2016-09-08 |
2020-02-27 |
Daiichi Sankyo Co Ltd |
Antibody for treating autoimmune diseases
|
|
CA3037380A1
(en)
*
|
2016-10-11 |
2018-04-19 |
Agenus Inc. |
Anti-lag-3 antibodies and methods of use thereof
|
|
UA127050C2
(uk)
|
2016-10-13 |
2023-03-29 |
Чіа Тай Тяньцин Фармасьютікал Груп Ко., Лтд. |
Ahtи-lag-3 антитіло i композиція, що містить його
|
|
CN110214148A
(zh)
|
2016-10-14 |
2019-09-06 |
Xencor股份有限公司 |
含有IL-15/IL-15Rα Fc融合蛋白和PD-1抗体片段的双特异性异源二聚体融合蛋白
|
|
KR102617873B1
(ko)
*
|
2016-10-28 |
2023-12-22 |
머크 샤프 앤드 돔 엘엘씨 |
티로신 황산화 항체 변이체의 제거를 위한 정제 프로세스, 정제된 조성물
|
|
MA46770A
(fr)
|
2016-11-09 |
2019-09-18 |
Agenus Inc |
Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
|
|
US11279694B2
(en)
|
2016-11-18 |
2022-03-22 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
|
FI3551660T3
(fi)
|
2016-12-07 |
2023-12-11 |
Agenus Inc |
Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä
|
|
CN108204958A
(zh)
*
|
2016-12-19 |
2018-06-26 |
伊缪泰普有限公司 |
结合测定
|
|
CN110462027A
(zh)
*
|
2017-01-06 |
2019-11-15 |
艾欧凡斯生物治疗公司 |
用肿瘤坏死因子受体超家族（tnfrsf）激动剂扩增肿瘤浸润淋巴细胞（til）及til和tnfrsf激动剂的治疗组合
|
|
WO2018134254A1
(en)
|
2017-01-17 |
2018-07-26 |
Heparegenix Gmbh |
Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
|
|
CN110944651A
(zh)
|
2017-02-08 |
2020-03-31 |
蜻蜓疗法股份有限公司 |
用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
|
|
BR112019016336A2
(pt)
|
2017-02-10 |
2020-03-31 |
Regeneron Pharmaceuticals, Inc. |
Conjugado de anticorpo radiorrotulado, método para imageamento de um tecido que expressa lag3 e para tratar um tumor, e, composto.
|
|
ES2955074T3
(es)
|
2017-02-20 |
2023-11-28 |
Dragonfly Therapeutics Inc |
Proteínas que se unen a HER2, NKG2D Y CD16
|
|
KR102236259B1
(ko)
|
2017-02-22 |
2021-04-06 |
아이-맵 바이오파마 유에스 리미티드 |
항-lag-3 항체 및 그것의 사용
|
|
PT3606946T
(pt)
|
2017-04-03 |
2022-10-17 |
Hoffmann La Roche |
Imunoconjugados de um anticorpo anti-pd-1 com uma il-2 mutante ou com il-15
|
|
CN116375876A
(zh)
|
2017-04-05 |
2023-07-04 |
豪夫迈·罗氏有限公司 |
特异性结合pd1和lag3的双特异性抗体
|
|
CN110621698B
(zh)
|
2017-04-05 |
2024-04-12 |
法国施维雅药厂 |
靶向pd-1、tim-3及lag-3的组合疗法
|
|
LT3606954T
(lt)
|
2017-04-05 |
2022-09-26 |
F. Hoffmann-La Roche Ag |
Anti-lag3 antikūnai
|
|
TWI796329B
(zh)
|
2017-04-07 |
2023-03-21 |
美商默沙東有限責任公司 |
抗－ilt4抗體及抗原結合片段
|
|
NZ759517A
(en)
*
|
2017-04-27 |
2025-02-28 |
Tesaro Inc |
Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
SG11201909955XA
(en)
*
|
2017-05-02 |
2019-11-28 |
Merck Sharp & Dohme |
Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
|
|
CN110621337B
(zh)
*
|
2017-05-10 |
2021-11-09 |
浙江时迈药业有限公司 |
抗lag3人单克隆抗体及其用途
|
|
BR112019021847A2
(pt)
|
2017-05-30 |
2020-06-02 |
Bristol-Myers Squibb Company |
Composições compreendendo um anticorpo anti-lag-3 ou um anticorpo anti-lag-3 e um anticorpo anti-pd-1 ou anti-pd-l1
|
|
HUE065242T2
(hu)
|
2017-05-30 |
2024-05-28 |
Bristol Myers Squibb Co |
LAG-3-pozitív tumorok kezelése
|
|
BR112019018759A2
(pt)
|
2017-05-30 |
2020-05-05 |
Bristol-Myers Squibb Company |
composições compreendendo uma combinação de um anticorpo anti-lag-3, um inibidor da via pd-1, e um agente imunoterápico
|
|
CN111032085A
(zh)
*
|
2017-06-05 |
2020-04-17 |
昆士兰医学研究所理事会 |
用于癌症治疗或预防的免疫检查点分子拮抗剂和rank-l（nf-kb配体）拮抗剂的组合或其双特异性结合分子及其用途
|
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
|
EP3641812A1
(en)
|
2017-06-22 |
2020-04-29 |
Novartis AG |
Antibody molecules to cd73 and uses thereof
|
|
WO2018235056A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
Il-1beta binding antibodies for use in treating cancer
|
|
AU2018287519B2
(en)
|
2017-06-22 |
2021-07-22 |
Novartis Ag |
IL-1beta binding antibodies for use in treating cancer
|
|
AU2018292618A1
(en)
|
2017-06-27 |
2019-12-19 |
Novartis Ag |
Dosage regimens for anti-TIM-3 antibodies and uses thereof
|
|
WO2019009728A1
(en)
*
|
2017-07-06 |
2019-01-10 |
Merus N.V. |
ANTIBODIES THAT MODULATE A BIOLOGICAL ACTIVITY EXPRESSED BY A CELL
|
|
US10844121B2
(en)
*
|
2017-07-13 |
2020-11-24 |
Nanjing Leads Biolabs Co., Ltd |
Antibodies binding LAG-3 and uses thereof
|
|
KR20250025039A
(ko)
|
2017-07-20 |
2025-02-20 |
노파르티스 아게 |
항-lag-3 항체의 투여 요법 및 그의 용도
|
|
AU2018308088B2
(en)
|
2017-07-25 |
2025-05-29 |
Truebinding, Inc. |
Treating cancer by blocking the interaction of TIM-3 and its ligand
|
|
EP3675898A4
(en)
*
|
2017-08-30 |
2021-09-01 |
Phanes Therapeutics, Inc. |
ANTI-LAG-3 ANTIBODIES AND THEIR USES
|
|
WO2019055579A1
(en)
|
2017-09-12 |
2019-03-21 |
Tolero Pharmaceuticals, Inc. |
TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
|
|
US20210040205A1
(en)
|
2017-10-25 |
2021-02-11 |
Novartis Ag |
Antibodies targeting cd32b and methods of use thereof
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
AU2018366199A1
(en)
*
|
2017-11-08 |
2020-05-28 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
|
|
AU2018368731A1
(en)
|
2017-11-16 |
2020-05-14 |
Novartis Ag |
Combination therapies
|
|
JOP20200131A1
(ar)
|
2017-11-17 |
2020-05-28 |
Merck Sharp & Dohme |
أجسام مضادة خاصة بنسخة تشبه جلوبيولين مناعي 3 (ilt3) واستخدامتها
|
|
TW201925782A
(zh)
|
2017-11-30 |
2019-07-01 |
瑞士商諾華公司 |
靶向bcma之嵌合抗原受體及其用途
|
|
CN111741976B
(zh)
|
2017-12-19 |
2024-09-17 |
英沃克斯制药有限公司 |
包括pd-l1抗原结合位点的fc结合片段
|
|
MX2020006322A
(es)
|
2017-12-19 |
2020-09-18 |
Xencor Inc |
Proteinas de fusion il-2 fc modificadas.
|
|
BR112020011664A2
(pt)
*
|
2017-12-22 |
2020-11-17 |
Jiangsu Hengrui Medicine Co., Ltd. |
composição farmacêutica do anticorpo lag-3 e seu uso
|
|
CN109970857B
(zh)
|
2017-12-27 |
2022-09-30 |
信达生物制药(苏州)有限公司 |
抗pd-l1抗体及其用途
|
|
CN109970856B
(zh)
|
2017-12-27 |
2022-08-23 |
信达生物制药(苏州)有限公司 |
抗lag-3抗体及其用途
|
|
WO2019129136A1
(zh)
|
2017-12-27 |
2019-07-04 |
信达生物制药(苏州)有限公司 |
抗pd-l1抗体及其用途
|
|
WO2019129137A1
(zh)
|
2017-12-27 |
2019-07-04 |
信达生物制药(苏州)有限公司 |
抗lag-3抗体及其用途
|
|
TW201930591A
(zh)
|
2018-01-08 |
2019-08-01 |
瑞士商諾華公司 |
用於與嵌合抗原受體療法併用之免疫增強rna
|
|
WO2019141092A1
(zh)
*
|
2018-01-18 |
2019-07-25 |
四川科伦博泰生物医药股份有限公司 |
抗lag-3抗体及其用途
|
|
CN108085393B
(zh)
*
|
2018-01-31 |
2020-06-02 |
青岛泱深生物医药有限公司 |
肾透明细胞癌相关生物标志物及其应用
|
|
CA3090249A1
(en)
|
2018-01-31 |
2019-08-08 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
|
WO2019148412A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3 bispecific antibodies
|
|
WO2019148410A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1 antibodies
|
|
EP3746119A4
(en)
*
|
2018-02-01 |
2021-11-10 |
Merck Sharp & Dohme Corp. |
METHOD OF TREATMENT FOR CANCER OR INFECTION USING A COMBINATION OF ANTI-PD-1 ANTIBODY, ANTI-LAG3 ANTIBODY, AND ANTI-TIGITE ANTIBODY
|
|
CA3090236A1
(en)
|
2018-02-08 |
2019-08-15 |
Dragonfly Therapeutics, Inc. |
Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
|
|
SG11202007482WA
(en)
|
2018-02-08 |
2020-09-29 |
Dragonfly Therapeutics Inc |
Antibody variable domains targeting the nkg2d receptor
|
|
WO2019160956A1
(en)
|
2018-02-13 |
2019-08-22 |
Novartis Ag |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
GB201802573D0
(en)
*
|
2018-02-16 |
2018-04-04 |
Crescendo Biologics Ltd |
Therapeutic molecules that bind to LAG3
|
|
KR102832460B1
(ko)
|
2018-02-20 |
2025-07-11 |
드래곤플라이 쎄라퓨틱스, 인크. |
Cd33, nkg2d, 및 cd16에 결합하는 다중-특이적 결합 단백질, 및 이의 사용 방법
|
|
TWI833738B
(zh)
*
|
2018-03-20 |
2024-03-01 |
中國大陸商上海藥明生物技術有限公司 |
新型抗lag-3抗體多肽
|
|
US11661452B2
(en)
|
2018-03-20 |
2023-05-30 |
WuXi Biologics Ireland Limited |
Anti-lag-3 antibody polypeptide
|
|
US20210024873A1
(en)
|
2018-03-27 |
2021-01-28 |
Bristol-Myers Squibb Company |
Real-time monitoring of protein concentration using ultraviolet signal
|
|
AU2019241350B2
(en)
|
2018-03-30 |
2025-10-02 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies against LAG-3 and uses thereof
|
|
WO2019192432A1
(zh)
*
|
2018-04-02 |
2019-10-10 |
上海博威生物医药有限公司 |
结合淋巴细胞活化基因-3(lag-3)的抗体及其用途
|
|
EP3774921A4
(en)
*
|
2018-04-03 |
2022-01-05 |
Dragonfly Therapeutics, Inc. |
ANTIBODY VARIABLE DOMAINS AGAINST DLL3 AND USE OF IT
|
|
CN112469477A
(zh)
|
2018-04-04 |
2021-03-09 |
Xencor股份有限公司 |
与成纤维细胞活化蛋白结合的异源二聚体抗体
|
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
|
AU2019256539A1
(en)
|
2018-04-18 |
2020-11-26 |
Xencor, Inc. |
PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
|
|
EP3781598A1
(en)
|
2018-04-18 |
2021-02-24 |
Xencor, Inc. |
Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
|
|
JP7368453B2
(ja)
*
|
2018-05-03 |
2023-10-24 |
シャンハイ エピムアブ バイオセラピューティクス カンパニー リミテッド |
Ｐｄ－１およびｌａｇ－３に対する高親和性抗体ならびにそれらから作製された二重特異性結合タンパク質
|
|
TWI869346B
(zh)
|
2018-05-30 |
2025-01-11 |
瑞士商諾華公司 |
Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
|
|
US20210214459A1
(en)
|
2018-05-31 |
2021-07-15 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
TWI848951B
(zh)
|
2018-06-01 |
2024-07-21 |
瑞士商諾華公司 |
針對ｂｃｍａ之結合分子及其用途
|
|
CA3103385A1
(en)
|
2018-07-10 |
2020-01-16 |
Novartis Ag |
3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
GB201811450D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Delta Ltd |
Mesothelin and CD137 binding molecules
|
|
GB201811415D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-Mesothelin Anti bodies
|
|
GB201811408D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
CD137 Binding Molecules
|
|
GB201811410D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
OX40 Binding molecules
|
|
GB201811403D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Antibody molecules
|
|
CN112423845B
(zh)
|
2018-07-12 |
2024-07-30 |
F-星治疗有限公司 |
结合pd-l1和cd137的抗体分子
|
|
CA3106048A1
(en)
|
2018-07-12 |
2020-01-16 |
F-Star Beta Limited |
Antibody molecules that bind cd137 and ox40
|
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
|
KR20210040080A
(ko)
|
2018-07-26 |
2021-04-12 |
브리스톨-마이어스 스큅 컴퍼니 |
암의 치료를 위한 lag-3 조합 요법
|
|
MX2021001527A
(es)
|
2018-08-08 |
2021-06-15 |
Dragonfly Therapeutics Inc |
Proteínas de unión a nkg2d, cd16 y a un antígeno asociado a tumor.
|
|
MA53293A
(fr)
|
2018-08-08 |
2021-11-17 |
Dragonfly Therapeutics Inc |
Protéines de liaison multi-spécifiques se liant à bcma, nkg2d et cd16, et méthodes d'utilisation
|
|
EA202091888A1
(ru)
|
2018-08-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Вариабельные домены антител, нацеленные на рецептор nkg2d
|
|
WO2020038397A1
(en)
*
|
2018-08-21 |
2020-02-27 |
I-Mab |
Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof
|
|
WO2020055702A1
(en)
|
2018-09-13 |
2020-03-19 |
Merck Sharp & Dohme Corp. |
Combination of pd-1 antagonist and lag3 antagonist for treating non-microsatellite instablity-high/proficient mismatch repair colorectal cancer
|
|
SG11202103192RA
(en)
|
2018-10-03 |
2021-04-29 |
Xencor Inc |
Il-12 heterodimeric fc-fusion proteins
|
|
PL3866850T3
(pl)
|
2018-10-19 |
2024-10-14 |
Bristol-Myers Squibb Company |
Terapia skojarzona czerniaka
|
|
WO2020089811A1
(en)
|
2018-10-31 |
2020-05-07 |
Novartis Ag |
Dc-sign antibody drug conjugates
|
|
JP7553439B2
(ja)
*
|
2018-11-05 |
2024-09-18 |
メルク・シャープ・アンド・ドーム・エルエルシー |
がんを処置するための抗ｌａｇ３抗体の投薬レジメンおよび抗ｐｄ－１抗体との組み合わせ治療
|
|
EP3876990A4
(en)
*
|
2018-11-07 |
2023-09-06 |
Merck Sharp & Dohme LLC |
CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
|
|
US11034710B2
(en)
|
2018-12-04 |
2021-06-15 |
Sumitomo Dainippon Pharma Oncology, Inc. |
CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
|
|
WO2020128972A1
(en)
|
2018-12-20 |
2020-06-25 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
CN113166762B
(zh)
|
2018-12-21 |
2025-01-14 |
瓦莱里奥治疗公司 |
新的偶联核酸分子及其用途
|
|
EP3897613A1
(en)
|
2018-12-21 |
2021-10-27 |
Novartis AG |
Use of il-1beta binding antibodies
|
|
AU2019406840A1
(en)
|
2018-12-21 |
2021-06-03 |
Novartis Ag |
Use of IL-1 beta antibodies in the treatment or prevention of myelodysplastic syndrome
|
|
EP3898674A1
(en)
|
2018-12-21 |
2021-10-27 |
Novartis AG |
Use of il-1beta binding antibodies
|
|
WO2020128637A1
(en)
|
2018-12-21 |
2020-06-25 |
Novartis Ag |
Use of il-1 binding antibodies in the treatment of a msi-h cancer
|
|
CA3127502A1
(en)
|
2019-02-12 |
2020-08-20 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Formulations comprising heterocyclic protein kinase inhibitors
|
|
ES2982474T3
(es)
|
2019-02-15 |
2024-10-16 |
Novartis Ag |
Derivados de 3-(1-oxoisoindolin-2-il)piperidin-1,6-diona sustituidos y usos de estos
|
|
ES3032659T3
(en)
|
2019-02-15 |
2025-07-23 |
Novartis Ag |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
US20220135619A1
(en)
|
2019-02-24 |
2022-05-05 |
Bristol-Myers Squibb Company |
Methods of isolating a protein
|
|
AU2020232605A1
(en)
|
2019-03-01 |
2021-10-21 |
Xencor, Inc. |
Heterodimeric antibodies that bind ENPP3 and CD3
|
|
US11793802B2
(en)
|
2019-03-20 |
2023-10-24 |
Sumitomo Pharma Oncology, Inc. |
Treatment of acute myeloid leukemia (AML) with venetoclax failure
|
|
WO2020198077A1
(en)
|
2019-03-22 |
2020-10-01 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Compositions comprising pkm2 modulators and methods of treatment using the same
|
|
EP3947640A4
(en)
|
2019-04-02 |
2022-12-14 |
The Brigham & Women's Hospital, Inc. |
PROCEDURE FOR DETERMINING THE PROGRESSION OF PRIMARY MELANOMA
|
|
WO2020216383A1
(en)
*
|
2019-04-26 |
2020-10-29 |
Single Cell Technology, Inc. |
Anti-lag-3 antibodies
|
|
WO2020236668A1
(en)
*
|
2019-05-17 |
2020-11-26 |
Gb006, Inc. |
Leukadherin-1 alone or in combination for use in the treatment of cancer
|
|
CA3141162A1
(en)
|
2019-05-22 |
2020-11-26 |
Leidos, Inc. |
Lag3 binding peptides
|
|
KR20220012292A
(ko)
|
2019-05-23 |
2022-02-03 |
브리스톨-마이어스 스큅 컴퍼니 |
세포 배양 배지를 모니터링하는 방법
|
|
US20220363760A1
(en)
|
2019-05-30 |
2022-11-17 |
Bristol-Myers Squibb Company |
Multi-tumor gene signature for suitability to immuno-oncology therapy
|
|
WO2020243570A1
(en)
|
2019-05-30 |
2020-12-03 |
Bristol-Myers Squibb Company |
Cell localization signature and combination therapy
|
|
JP2022534982A
(ja)
|
2019-05-30 |
2022-08-04 |
ブリストル－マイヤーズ スクイブ カンパニー |
細胞局在化シグネチャーおよびその使用
|
|
US11529350B2
(en)
|
2019-07-03 |
2022-12-20 |
Sumitomo Pharma Oncology, Inc. |
Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
|
|
CA3139314A1
(en)
*
|
2019-07-17 |
2021-01-21 |
Noxopharm Limited |
Immuno-oncology therapy using isoflavone compounds
|
|
US20220251194A1
(en)
*
|
2019-07-30 |
2022-08-11 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3/tigit trispecific antibodies and anti-pd-1/lag3 bicpecific antibodies
|
|
WO2021024020A1
(en)
|
2019-08-06 |
2021-02-11 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
|
|
US20220348651A1
(en)
|
2019-09-18 |
2022-11-03 |
Novartis Ag |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
|
WO2021055994A1
(en)
|
2019-09-22 |
2021-03-25 |
Bristol-Myers Squibb Company |
Quantitative spatial profiling for lag-3 antagonist therapy
|
|
CN114786679A
(zh)
|
2019-10-21 |
2022-07-22 |
诺华股份有限公司 |
具有维奈托克和tim-3抑制剂的组合疗法
|
|
CN114786680A
(zh)
|
2019-10-21 |
2022-07-22 |
诺华股份有限公司 |
Tim-3抑制剂及其用途
|
|
WO2021092220A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
|
WO2021092221A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
|
US20220411499A1
(en)
|
2019-11-08 |
2022-12-29 |
Bristol-Myers Squibb Company |
LAG-3 Antagonist Therapy for Melanoma
|
|
JP2023500385A
(ja)
*
|
2019-11-11 |
2023-01-05 |
シーストーン・ファーマシューティカルズ・（スージョウ）・カンパニー・リミテッド |
医薬組合せ物およびその使用
|
|
WO2021126967A1
(en)
*
|
2019-12-20 |
2021-06-24 |
Merck Sharp & Dohme Corp. |
Lag3 antagonist cell based potency assay
|
|
MX2022007759A
(es)
|
2019-12-20 |
2022-07-19 |
Novartis Ag |
Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico.
|
|
EP4090335A1
(en)
|
2020-01-17 |
2022-11-23 |
Novartis AG |
Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
|
|
KR20220131279A
(ko)
*
|
2020-01-21 |
2022-09-27 |
상하이 헨리우스 바이오테크, 인크. |
항lag3단일 클론 항체 및 그 제조 방법과 응용
|
|
EP4096802A4
(en)
*
|
2020-01-29 |
2024-07-03 |
Merck Sharp & Dohme LLC |
METHOD FOR SEPARATION OF HOST CELL LIPASES FROM ANTI-LAG3 ANTIBODY PRODUCTION
|
|
US20230087600A1
(en)
|
2020-02-06 |
2023-03-23 |
Bristol-Myers Squibb Company |
Il-10 and uses thereof
|
|
KR102245082B1
(ko)
*
|
2020-02-14 |
2021-04-26 |
단국대학교 천안캠퍼스 산학협력단 |
치주인대전구세포 표면에 특이적으로 결합하는 두 가지 IgG 타입 단일클론항체 LG43, LG73 및 그의 용도
|
|
JP2023519990A
(ja)
|
2020-03-30 |
2023-05-15 |
ノクソファーム リミティド |
感染に関連する炎症の治療のための方法
|
|
US20230184771A1
(en)
*
|
2020-04-21 |
2023-06-15 |
Board Of Regents, The University Of Texas System |
Methods for treating bladder cancer
|
|
WO2021217117A1
(en)
*
|
2020-04-24 |
2021-10-28 |
Memorial Sloan Kettering Cancer Center |
Targeted therapy for the treatment & prevention of life-threatening complications of infection
|
|
MX2022013944A
(es)
|
2020-05-06 |
2022-11-30 |
Dragonfly Therapeutics Inc |
Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).
|
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
|
US12281166B2
(en)
|
2020-05-26 |
2025-04-22 |
Truebinding, Inc. |
Methods of treating inflammatory diseases by blocking Galectin-3
|
|
CA3185657A1
(en)
|
2020-06-04 |
2021-12-09 |
Leidos, Inc. |
Immunomodulatory compounds
|
|
CN111808192B
(zh)
*
|
2020-06-05 |
2022-02-15 |
北京天广实生物技术股份有限公司 |
结合lag3的抗体及其用途
|
|
AR122644A1
(es)
|
2020-06-19 |
2022-09-28 |
Onxeo |
Nuevas moléculas de ácido nucleico conjugado y sus usos
|
|
MX2022015852A
(es)
|
2020-06-23 |
2023-01-24 |
Novartis Ag |
Regimen de dosificacion que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona.
|
|
MX2023000197A
(es)
|
2020-07-07 |
2023-02-22 |
BioNTech SE |
Arn terapeutico para el cancer positivo para vph.
|
|
EP4188947A2
(en)
*
|
2020-07-31 |
2023-06-07 |
Leidos, Inc. |
Lag3 binding peptides
|
|
EP4188549A1
(en)
|
2020-08-03 |
2023-06-07 |
Novartis AG |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
KR102607909B1
(ko)
|
2020-08-19 |
2023-12-01 |
젠코어 인코포레이티드 |
항-cd28 조성물
|
|
CA3193421A1
(en)
|
2020-08-28 |
2022-03-03 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for hepatocellular carcinoma
|
|
EP4204020A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
|
US20230321285A1
(en)
|
2020-08-31 |
2023-10-12 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
EP4204453A1
(en)
|
2020-08-31 |
2023-07-05 |
Bristol-Myers Squibb Company |
Cell localization signature and immunotherapy
|
|
CN116406369A
(zh)
|
2020-10-05 |
2023-07-07 |
百时美施贵宝公司 |
用于浓缩蛋白质的方法
|
|
EP4232019A1
(en)
|
2020-10-23 |
2023-08-30 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for lung cancer
|
|
AU2021373366A1
(en)
|
2020-11-06 |
2023-06-01 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
|
WO2022109987A1
(en)
*
|
2020-11-27 |
2022-06-02 |
Shanghai Benemae Pharmaceutical Corporation |
Novel anti-lag3 antibodies and methods of making and using the same
|
|
JP2024508207A
(ja)
|
2020-12-02 |
2024-02-26 |
ブイアイビー ブイゼットダブリュ |
がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト
|
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
|
CN115819585B
(zh)
*
|
2020-12-10 |
2023-06-02 |
北京东方百泰生物科技股份有限公司 |
一种抗lag-3的单克隆抗体、其抗原结合片段及其应用
|
|
TW202237119A
(zh)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Ａｌｋ﹘５抑制劑和彼之用途
|
|
TW202245808A
(zh)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
用於治療癌症之治療性ｒｎａ
|
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
|
US20220233689A1
(en)
|
2020-12-28 |
2022-07-28 |
Bristol-Myers Squibb Company |
Methods of treating tumors
|
|
RS66849B1
(sr)
|
2020-12-28 |
2025-06-30 |
Bristol Myers Squibb Co |
Kompozicije antitela i postupci njihove upotrebe
|
|
US20240384350A1
(en)
|
2021-01-29 |
2024-11-21 |
Board Of Regents, The University Of Texas System |
Methods of treating cancer with kinase inhibitors
|
|
WO2022187539A1
(en)
|
2021-03-03 |
2022-09-09 |
Dragonfly Therapeutics, Inc. |
Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
|
|
WO2022189936A1
(en)
*
|
2021-03-08 |
2022-09-15 |
Medimmune, Llc |
Antibodies directed against gdf-15
|
|
JP2024511319A
(ja)
|
2021-03-09 |
2024-03-13 |
ゼンコア インコーポレイテッド |
Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体
|
|
JP2024509274A
(ja)
|
2021-03-10 |
2024-02-29 |
ゼンコア インコーポレイテッド |
Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
|
|
KR20240005700A
(ko)
|
2021-03-29 |
2024-01-12 |
주노 쎄러퓨티크스 인코퍼레이티드 |
체크포인트 억제제 요법 및 car t 세포 요법의 조합을 사용한 투여 및 치료 방법
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
WO2022216979A1
(en)
|
2021-04-08 |
2022-10-13 |
Board Of Regents, The University Of Texas System |
Compounds and methods for theranostic targeting of parp activity
|
|
EP4323356A1
(en)
|
2021-04-13 |
2024-02-21 |
Nuvalent, Inc. |
Amino-substituted heterocycles for treating cancers with egfr mutations
|
|
US20240285740A1
(en)
|
2021-05-12 |
2024-08-29 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating cancer
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
CN115403670A
(zh)
|
2021-05-26 |
2022-11-29 |
安徽瀚海博兴生物技术有限公司 |
抗cd40抗体及其用途
|
|
CA3225254A1
(en)
|
2021-07-13 |
2023-01-19 |
BioNTech SE |
Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
|
|
CN115611983A
(zh)
|
2021-07-14 |
2023-01-17 |
三优生物医药(上海)有限公司 |
Cldn18.2结合分子及其用途
|
|
KR20240051178A
(ko)
*
|
2021-08-17 |
2024-04-19 |
웨어울프 세라퓨틱스, 인크. |
유도성 il-2 및 pd-1/pd-l1 병용 요법
|
|
WO2023051621A1
(zh)
*
|
2021-09-29 |
2023-04-06 |
中山康方生物医药有限公司 |
抗lag3抗体、药物组合物及用途
|
|
TW202333802A
(zh)
|
2021-10-11 |
2023-09-01 |
德商拜恩迪克公司 |
用於肺癌之治療性rna(二)
|
|
WO2023077090A1
(en)
|
2021-10-29 |
2023-05-04 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for hematological cancer
|
|
EP4426739A1
(en)
*
|
2021-11-01 |
2024-09-11 |
Elpiscience (Suzhou) Biopharma, Ltd. |
Novel anti-lag3 antibodies
|
|
IL313439A
(en)
|
2021-12-16 |
2024-08-01 |
Valerio Therapeutics |
New conjugated nucleic acid molecules and their uses
|
|
JP2025503962A
(ja)
|
2022-01-26 |
2025-02-06 |
ブリストル－マイヤーズ スクイブ カンパニー |
肝細胞がんのための併用療法
|
|
US20250327041A1
(en)
|
2022-02-24 |
2025-10-23 |
Io Biotech Aps |
Nucleotide delivery of cancer therapy
|
|
JP2025507694A
(ja)
|
2022-02-25 |
2025-03-21 |
ブリストル－マイヤーズ スクイブ カンパニー |
結腸直腸癌に対する組み合わせ療法
|
|
WO2023168404A1
(en)
|
2022-03-04 |
2023-09-07 |
Bristol-Myers Squibb Company |
Methods of treating a tumor
|
|
AU2023230110A1
(en)
|
2022-03-08 |
2024-10-24 |
Alentis Therapeutics Ag |
Use of anti-claudin-1 antibodies to increase t cell availability
|
|
WO2023173011A1
(en)
|
2022-03-09 |
2023-09-14 |
Bristol-Myers Squibb Company |
Transient expression of therapeutic proteins
|
|
JP2025509832A
(ja)
|
2022-03-15 |
2025-04-11 |
コンピュジェン リミテッド |
Ｉｌ－１８ｂｐアンタゴニスト抗体、並びに癌の治療での単剤療法及び併用療法におけるそれらの使用
|
|
KR20240159621A
(ko)
|
2022-03-18 |
2024-11-05 |
브리스톨-마이어스 스큅 컴퍼니 |
폴리펩티드를 단리하는 방법
|
|
CN114634574B
(zh)
*
|
2022-04-18 |
2022-12-20 |
先进生物(苏州)有限公司 |
抗B7H6的scFv抗体、其编码基因及其应用
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
AU2023281061A1
(en)
|
2022-06-02 |
2024-12-05 |
Bristol-Myers Squibb Company |
Antibody compositions and methods of use thereof
|
|
WO2024102603A1
(en)
*
|
2022-11-07 |
2024-05-16 |
Merck Sharp & Dohme Llc |
Bisecting-glycan bridged conjugation for producing glycoprotein conjugates
|
|
CN120390652A
(zh)
|
2022-12-01 |
2025-07-29 |
免疫医疗有限公司 |
用于治疗癌症的包含抗pd-l1抗体和抗cd73抗体的组合疗法
|
|
AU2023393653A1
(en)
|
2022-12-14 |
2025-05-22 |
Astellas Pharma Europe Bv |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
|
|
AU2023409221A1
(en)
|
2022-12-21 |
2025-06-12 |
Bristol-Myers Squibb Company |
Combination therapy for lung cancer
|
|
WO2024163477A1
(en)
|
2023-01-31 |
2024-08-08 |
University Of Rochester |
Immune checkpoint blockade therapy for treating staphylococcus aureus infections
|
|
WO2024173876A1
(en)
|
2023-02-17 |
2024-08-22 |
Regeneron Pharmaceuticals, Inc. |
Radiolabeled anti-lag3 antibodies for immuno-pet imaging
|
|
AU2024225483A1
(en)
|
2023-02-23 |
2025-08-28 |
Imcheck Therapeutics |
Combination of btn3a activating antibody and immune checkpoint inhibitors
|
|
CN120835901A
(zh)
|
2023-03-13 |
2025-10-24 |
豪夫迈·罗氏有限公司 |
采用pd1-lag3双特异性抗体和hla-g t细胞双特异性抗体的组合疗法
|
|
WO2024196952A1
(en)
|
2023-03-20 |
2024-09-26 |
Bristol-Myers Squibb Company |
Tumor subtype assessment for cancer therapy
|
|
TW202515608A
(zh)
|
2023-06-26 |
2025-04-16 |
以色列商坎布根有限公司 |
Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途
|
|
WO2025038763A1
(en)
|
2023-08-15 |
2025-02-20 |
Bristol-Myers Squibb Company |
Ceramic hydroxyapatite chromatography flow through method
|
|
WO2025054110A1
(en)
*
|
2023-09-07 |
2025-03-13 |
Merck Sharp & Dohme Llc |
Combination therapy of a pd-1 antagonist and lag3 antagonist for treating patients with cancer before and/or after surgery
|
|
WO2025068461A1
(en)
|
2023-09-29 |
2025-04-03 |
Negio Therapeutics |
Guanfacine derivatives and their use in treating cancer
|
|
WO2025068452A1
(en)
|
2023-09-29 |
2025-04-03 |
Negio Therapeutics |
Guanfacine derivatives and their use in treating cancer
|
|
TW202535926A
(zh)
|
2023-10-30 |
2025-09-16 |
美商再生元醫藥公司 |
穩定抗體配製物
|
|
WO2025120867A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
|
|
WO2025120866A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
WO2025121445A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
WO2025132831A1
(en)
|
2023-12-19 |
2025-06-26 |
Universite D'aix-Marseille |
N-heteroaryl derivatives and uses thereof for treating cancer
|
|
WO2025145207A1
(en)
|
2023-12-29 |
2025-07-03 |
Bristol-Myers Squibb Company |
Combination therapy of kras inhibitor and treg-depleting agent
|
|
EP4658320A1
(en)
|
2024-02-27 |
2025-12-10 |
Bristol-Myers Squibb Company |
Anti-ceacam5 antibody drug conjugates
|
|
US20250361320A1
(en)
|
2024-02-27 |
2025-11-27 |
Bristol-Myers Squibb Company |
Anti-ceacam5 antibodies and uses thereof
|
|
WO2025202213A1
(en)
|
2024-03-26 |
2025-10-02 |
Institut National de la Santé et de la Recherche Médicale |
Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells
|
|
WO2025226695A1
(en)
|
2024-04-23 |
2025-10-30 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
|
WO2025245489A1
(en)
|
2024-05-24 |
2025-11-27 |
Bristol-Myers Squibb Company |
Treatment of tumors in subjects having fgl-1 positive samples
|